Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics

Archive ouverte

Quesada, Stanislas | Penault-Llorca, Frédérique | Matias-Guiu, Xavier | Banerjee, Susana | Barberis, Massimo | Coleman, Robert | Colombo, Nicoletta | Defazio, Anna | Mcneish, Iain | Nogueira-Rodrigues, Angélica | Oaknin, Ana | Pignata, Sandro | Pujade-Lauraine, Éric | Rouleau, Étienne | Ryška, Aleš | van der Merwe, Nerina | van Gorp, Toon | Vergote, Ignace | Weichert, Wilko | Wu, Xiaohua | Ray-Coquard, Isabelle | Pujol, Pascal

Edité par CCSD ; Elsevier -

International audience. Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency (HRD) may influence treatment decision-making in this setting. As a result, numerous companion diagnostic assays (CDx) have been developed to identify HRD. However, the optimal HRD testing strategy is an area of debate. Moreover, recently published clinical and translational data may impact how HRD status may be used to identify patients likely to benefit from PARPi use. We aimed to extensively compare available HRD CDx and establish a worldwide expert consensus on HRD testing in primary and recurrent OC.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion